Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
February 27, 2024 16:01 ET
|
Ventyx Biosciences, Inc.
Ventyx to host virtual investor event on March 11th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis Cash, cash...
Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO)
February 22, 2024 07:00 ET
|
Ventyx Biosciences, Inc.
Results of the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis to be highlighted in oral presentation on February 22nd SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ventyx...
Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024 16:05 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference
November 21, 2023 16:05 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference
November 10, 2023 08:00 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
November 09, 2023 16:01 ET
|
Ventyx Biosciences, Inc.
Ventyx to provide updates across clinical-stage portfolio in the first quarter of 2024 Cash, cash equivalents and marketable securities of $300.8 million as of September 30, 2023 SAN DIEGO, Nov....
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update
November 06, 2023 16:01 ET
|
Ventyx Biosciences, Inc.
VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16 Efficacy results did not meet the internal target...
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis
October 09, 2023 16:01 ET
|
Ventyx Biosciences, Inc.
VTX002 60 mg achieved the primary endpoint of clinical remission with a high rate of complete endoscopic remission Both 30 mg and 60 mg doses of VTX002 demonstrated an excellent safety and...
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
August 30, 2023 16:05 ET
|
Ventyx Biosciences, Inc.
SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a...
Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress
August 10, 2023 16:01 ET
|
Ventyx Biosciences, Inc.
Completed enrollment in the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis, with topline readouts expected in Q4...